View in EDS

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Saved in:
Bibliographic Details
Title: Therapeutic potential of ERK5 targeting in triple negative breast cancer.
Authors: Ortiz-Ruiz MJ; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Álvarez-Fernández S; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Parrott T; Tragara Pharmaceuticals, Carlsbad, CA, USA., Zaknoen S; Tragara Pharmaceuticals, Carlsbad, CA, USA., Burrows FJ; Tragara Pharmaceuticals, Carlsbad, CA, USA., Ocaña A; Hospital Universitario de Albacete, and AECC Unit, Spain., Pandiella A; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Esparís-Ogando A; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.
Source: Oncotarget [Oncotarget] 2014 Nov 30; Vol. 5 (22), pp. 11308-18.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25350956
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Therapeutic potential of ERK5 targeting in triple negative breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ortiz-Ruiz+MJ%22">Ortiz-Ruiz MJ</searchLink>; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.<br /><searchLink fieldCode="AU" term="%22Álvarez-Fernández+S%22">Álvarez-Fernández S</searchLink>; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.<br /><searchLink fieldCode="AU" term="%22Parrott+T%22">Parrott T</searchLink>; Tragara Pharmaceuticals, Carlsbad, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zaknoen+S%22">Zaknoen S</searchLink>; Tragara Pharmaceuticals, Carlsbad, CA, USA.<br /><searchLink fieldCode="AU" term="%22Burrows+FJ%22">Burrows FJ</searchLink>; Tragara Pharmaceuticals, Carlsbad, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ocaña+A%22">Ocaña A</searchLink>; Hospital Universitario de Albacete, and AECC Unit, Spain.<br /><searchLink fieldCode="AU" term="%22Pandiella+A%22">Pandiella A</searchLink>; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.<br /><searchLink fieldCode="AU" term="%22Esparís-Ogando+A%22">Esparís-Ogando A</searchLink>; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101532965%22">Oncotarget</searchLink> [Oncotarget] 2014 Nov 30; Vol. 5 (22), pp. 11308-18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Impact+Journals%22">Impact Journals </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101532965 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1949-2553 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219492553%22">19492553 </searchLink><i>NLM ISO Abbreviation: </i>Oncotarget <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25350956
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.18632/oncotarget.2324
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 11308
    Titles:
      – TitleFull: Therapeutic potential of ERK5 targeting in triple negative breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ortiz-Ruiz MJ
      – PersonEntity:
          Name:
            NameFull: Álvarez-Fernández S
      – PersonEntity:
          Name:
            NameFull: Parrott T
      – PersonEntity:
          Name:
            NameFull: Zaknoen S
      – PersonEntity:
          Name:
            NameFull: Burrows FJ
      – PersonEntity:
          Name:
            NameFull: Ocaña A
      – PersonEntity:
          Name:
            NameFull: Pandiella A
      – PersonEntity:
          Name:
            NameFull: Esparís-Ogando A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 11
              Text: 2014 Nov 30
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-electronic
              Value: 1949-2553
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 22
          Titles:
            – TitleFull: Oncotarget
              Type: main
ResultId 1